Literature DB >> 2676559

The clinical effect of felodipine and nifedipine in Raynaud's phenomenon.

J F Schmidt1, N Valentin, S L Nielsen.   

Abstract

Sixteen patients participated in a double-blind cross-over trial comparing the effect of two dosages of the new calcium entry blocker, felodipine, with nifedipine in the treatment of Raynaud's phenomenon. The effect was evaluated using a symptom recording system. As no difference was found between the 3 treatments, the lower dose of felodipine (10 mg) may be preferable as only one dose per day is necessary.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2676559     DOI： 10.1007/bf00558230

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


  7 in total

1.  The importance of beta, the type II error and sample size in the design and interpretation of the randomized control trial. Survey of 71 "negative" trials.

Authors:  J A Freiman; T C Chalmers; H Smith; R R Kuebler
Journal:  N Engl J Med       Date:  1978-09-28       Impact factor: 91.245

2.  Controlled double-blind trial of the clinical effect of nifedipine in the treatment of idiopathic Raynaud's phenomenon.

Authors:  T Gjørup; H Kelbaek; O J Hartling; S L Nielsen
Journal:  Am Heart J       Date:  1986-04       Impact factor: 4.749

3.  Controlled double-blind trial of nifedipine in the treatment of Raynaud's phenomenon.

Authors:  R J Rodeheffer; J A Rommer; F Wigley; C R Smith
Journal:  N Engl J Med       Date:  1983-04-14       Impact factor: 91.245

4.  [Calculation of test power in clinical research].

Authors:  J J Krintel; O S Haxholdt
Journal:  Ugeskr Laeger       Date:  1985-04-01

5.  Prevalence of primary Raynaud phenomena in young females.

Authors:  N Olsen; S L Nielsen
Journal:  Scand J Clin Lab Invest       Date:  1978-12       Impact factor: 1.713

6.  Controlled trial of nifedipine in the treatment of Raynaud's phenomenon.

Authors:  C D Smith; R J McKendry
Journal:  Lancet       Date:  1982-12-11       Impact factor: 79.321

7.  Vascular selectivity of felodipine.

Authors:  B Ljung
Journal:  Drugs       Date:  1985       Impact factor: 9.546
  7 in total
  9 in total

1.  Raynaud's Phenomenon.

Authors: 
Journal:  Curr Treat Options Cardiovasc Med       Date:  2000-06

2.  Once daily felodipine in patients with primary Raynaud's phenomenon.

Authors:  C G Kallenberg; A A Wouda; L Meems; H Wesseling
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 3.  [Raynaud phenomenon in dermatology : Part 2: therapy].

Authors:  C Sunderkötter; G Riemekasten
Journal:  Hautarzt       Date:  2006-10       Impact factor: 0.751

4.  [Primary and secondary Raynaud's phenomenon].

Authors:  J H W Distler
Journal:  Z Rheumatol       Date:  2008-05       Impact factor: 1.372

Review 5.  [Evidence-based therapy of Raynaud's syndrome].

Authors:  M Distler; J Distler; A Ciurea; D Kyburz; U Müller-Ladner; K Reich; O Distler
Journal:  Z Rheumatol       Date:  2006-07       Impact factor: 1.372

Review 6.  Scleroderma therapy: clinical overview of current trends and future perspective.

Authors:  Afsha A Topal; Rachita S Dhurat
Journal:  Rheumatol Int       Date:  2012-08-03       Impact factor: 2.631

Review 7.  Felodipine. A review of the pharmacology and therapeutic use of the extended release formulation in cardiovascular disorders.

Authors:  P A Todd; D Faulds
Journal:  Drugs       Date:  1992-08       Impact factor: 9.546

Review 8.  Felodipine. A review of the pharmacology and therapeutic use of the extended release formulation in older patients.

Authors:  D Faulds; E M Sorkin
Journal:  Drugs Aging       Date:  1992 Sep-Oct       Impact factor: 3.923

Review 9.  Calcium channel blockers for primary Raynaud's phenomenon.

Authors:  Holly Ennis; Michael Hughes; Marina E Anderson; Jack Wilkinson; Ariane L Herrick
Journal:  Cochrane Database Syst Rev       Date:  2016-02-25
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.